Coronary In-Stent Restenosis: JACC State-of-the-Art Review
- PMID: 35863852
- DOI: 10.1016/j.jacc.2022.05.017
Coronary In-Stent Restenosis: JACC State-of-the-Art Review
Abstract
The introduction and subsequent iterations of drug-eluting stent technologies have substantially improved the efficacy and safety of percutaneous coronary interventions. However, the incidence of in-stent restenosis (ISR) and the resultant need for repeated revascularization still occur at a rate of 1%-2% per year. Given that millions of drug-eluting stents are implanted each year around the globe, ISR can be considered as a pathologic entity of public health significance. The mechanisms of ISR are multifactorial. Since the first description of the angiographic patterns of ISR, the advent of intracoronary imaging has further elucidated the mechanisms and patterns of ISR. The armamentarium and treatment strategies of ISR have also evolved over time. Currently, an individualized approach using intracoronary imaging to characterize the underlying substrate of ISR is recommended. In this paper, we comprehensively reviewed the incidence, mechanisms, and imaging characterization of ISR and propose a contemporary treatment algorithm.
Keywords: coronary artery disease; drug-eluting stent; in-stent restenosis; revascularization.
Copyright © 2022 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Funding Support and Author Disclosures Dr Giustino has received advisory board fees from Bristol Myers Squibb/Pfizer. Dr Mehran has received institutional research payments from Abbott, Abiomed, Alleviant Medical, AM-Pharma, Applied Therapeutics, Arena, AstraZeneca, BAIM, Bayer, Beth Israel Deaconess, Biosensors, Biotronik, Boston Scientific, Bristol Myers Squibb, CardiaWave, CellAegis, CeloNova, CERC, Chiesi, Concept Medical, CSL Behring, DSI, Duke University, Element Science, Humacyte, Insel Gruppe, Janssen, Magenta, Medtronic, Novartis, OrbusNeich, Philips, Vivasure, and Zoll, Dr Stone has received speaker and other honoraria from Cook, Terumo, Orchestra Biomed, and Qool Therapeutics; has served as a consultant to TherOx, Reva, Vascular Dynamics, Robocath, HeartFlow, Gore, Ablative Solutions, Matrizyme, Miracor, Neovasc, V-Wave, Abiomed, Shockwave, MAIA Pharmaceuticals, Cardiomech, SpectraWave, Valfix, Ancora, and Vectorious; and owns equity/options in Applied Therapeutics, Biostar family of funds, MedFocus family of funds, Aria, Cardiac Success, Cagent, SpectraWave, Valfix, Ancora, Orchestra Biomed, and Qool Therapeutics. Dr Sharma has received honoraria as a Speakers Bureau member from Abbott Vascular, Boston Scientific, and Cardiovascular Systems. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Similar articles
-
From Mechanisms to Management: Tackling In-Stent Restenosis in the Drug-Eluting Stent Era.Curr Cardiol Rep. 2025 Feb 11;27(1):53. doi: 10.1007/s11886-025-02193-z. Curr Cardiol Rep. 2025. PMID: 39932602 Free PMC article. Review.
-
Stent failure: the diagnosis and management of intracoronary stent restenosis.Expert Rev Cardiovasc Ther. 2023 Jul-Dec;21(7):501-506. doi: 10.1080/14779072.2023.2221852. Epub 2023 Jun 5. Expert Rev Cardiovasc Ther. 2023. PMID: 37269322 Review.
-
Restenosis of Drug-Eluting Stents: A New Classification System Based on Disease Mechanism to Guide Treatment and State-of-the-Art Review.Circ Cardiovasc Interv. 2019 Aug;12(8):e007023. doi: 10.1161/CIRCINTERVENTIONS.118.007023. Epub 2019 Jul 26. Circ Cardiovasc Interv. 2019. PMID: 31345066 Review.
-
Drug-Eluting Stent Restenosis: Modern Approach to a Classic Challenge.Curr Cardiol Rev. 2023;19(3):e030123212355. doi: 10.2174/1573403X19666230103154638. Curr Cardiol Rev. 2023. PMID: 36597603 Free PMC article. Review.
-
Resistant in-stent restenosis in the drug eluting stent era.Catheter Cardiovasc Interv. 2016 Nov;88(5):777-785. doi: 10.1002/ccd.26559. Epub 2016 May 17. Catheter Cardiovasc Interv. 2016. PMID: 27184223
Cited by
-
Bivalirudin vs heparin in cardiac-cerebral ischemic and bleeding events among Chinese STEMI patients during percutaneous coronary intervention: a retrospective cohort study.Braz J Med Biol Res. 2023 Nov 13;56:e13013. doi: 10.1590/1414-431X2023e13013. eCollection 2023. Braz J Med Biol Res. 2023. PMID: 37970924 Free PMC article.
-
Changes in serum uteroglobin level in type 2 diabetes mellitus patients.Front Endocrinol (Lausanne). 2024 Sep 30;15:1416326. doi: 10.3389/fendo.2024.1416326. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 39403586 Free PMC article.
-
Efficacy of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Treatment for Repeated In-stent Restenosis in a Coronary Artery.Intern Med. 2023 Nov 15;62(22):3361-3365. doi: 10.2169/internalmedicine.1609-23. Epub 2023 Mar 31. Intern Med. 2023. PMID: 37005262 Free PMC article.
-
Sacubitril/valsartan inhibits the proliferation of vascular smooth muscle cells through notch signaling and ERK1/2 pathway.BMC Cardiovasc Disord. 2024 Feb 14;24(1):106. doi: 10.1186/s12872-024-03764-8. BMC Cardiovasc Disord. 2024. PMID: 38355423 Free PMC article.
-
Influence of remnant lipoprotein particle cholesterol on non-target lesions progression in patients undergoing percutaneous coronary intervention.Front Cardiovasc Med. 2024 Dec 10;11:1471479. doi: 10.3389/fcvm.2024.1471479. eCollection 2024. Front Cardiovasc Med. 2024. PMID: 39720212 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources